Sanofi S.A., FR0000120578

Sanofi stock: Leerink Partners sets EUR 94.00 target for Sanofi stock

Published on 10/20/2026 at 15:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi targets insulin production in 2032. Sanofi stock costs EUR 72.18 on October 20, 2026, up 1.65 percent versus the Xetra close.

Analyst target and plant investment

Leerink Partners set a EUR 94.00 target for Sanofi on October 19, 2026.
Sanofi plans full insulin production at its Frankfurt facility for 2032.
Sanofi stock costs EUR 72.18 at Lang & Schwarz on October 20, 2026 at 3:15 p.m. CEST, 1.65 percent above the Xetra close of October 19, 2026.
Third-quarter 2026 results are scheduled for October 30, 2026.

Delicate watercolor painting of a Parisian research campus with a central stone fountain, modern glass pavilions and classic Haussmann buildings under a violet sky — Sanofi FR0000120578 watercolor Parisian pharmaceutical research campus with fountain and glass-and-stone research pavilions, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) received a EUR 94.00 price target from Leerink Partners on October 19, 2026, while the company advanced a long-term insulin investment in Germany. According to Markets Insider, the firm maintained a Buy rating and set the target at EUR 94.00. Sanofi stock was trading at EUR 72.18 at Lang & Schwarz on October 20, 2026 at 3:15 p.m. CEST, 1.65 percent above the Xetra close of October 19, 2026 at EUR 71.01.

Insulin investment reaches 2032

Sanofi broke ground on October 19, 2026, for a new insulin manufacturing facility at its BioCampus in Frankfurt. The company said in its Sanofi press release that the site will cover 36,000 square meters and that full production of insulin active pharmaceutical ingredient is planned for 2032. The facility will use automation, digital technologies and artificial intelligence in production and quality processes.

Price position and target distance

The Leerink target stands 30.20 percent above the Lang & Schwarz price, calculated from EUR 94.00 and EUR 72.18. A separate UBS assessment dated October 14, 2026 kept a Neutral rating and a EUR 78.00 target ahead of Sanofi's third-quarter results, according to FinanzNachrichten. That target is 8.07 percent above the Lang & Schwarz price.

Valuation and reporting dates

Sanofi is listed on Euronext Paris under ticker SAN and on Nasdaq under ticker SNY, according to the company release. Sanofi's investor calendar lists third-quarter 2026 results for October 30, 2026, with a management presentation and question-and-answer session, and a fourth-quarter and full-year 2026 results event for January 28, 2027, according to Sanofi.

What does the target imply?

The two recent targets frame Sanofi between EUR 78.00 and EUR 94.00, a spread of EUR 16.00. The lower target places greater weight on the upcoming third-quarter report, while the higher target reflects a more constructive view of the stock's potential.

Stock position after the update

Sanofi's current euro price is 1.65 percent above the October 19 Xetra close. The next company date is October 30, 2026, when management is scheduled to discuss third-quarter results.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.